Center-Authored Papers

Filters: Author is Willman, Cheryl L  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
T
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH et al..  2010.  Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group. Blood. 116(25):5650-9. Abstract
S
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf SH, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR et al..  2011.  A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.. Blood. 118(3):523-8. Abstract
R
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M, Pei D, Iacobucci I, Valentine M, Pounds SB et al..  2016.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2016690073. Abstract
P
Pogosova-Agadjanyan EL, Kopecky KJ, Ostronoff F, Appelbaum FR, Godwin J, Lee H, List AF, May JJ, Oehler VG, Petersdorf S et al..  2013.  The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia.. PloS one. 8(8):e70812. Abstract
O
Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A et al..  2015.  Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(10):1157-64. Abstract
Ostronoff F, Othus M, Kantarjian HM, Meshinchi S, Ravandi F, Hendrie PC, Faderl S, Becker PS, Cortes JE, Pagel JM et al..  2013.  A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia.. British journal of haematology. 163(1):130-2.
N
Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR.  2013.  A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.. Blood. 122(20):3432-3439. Abstract
K
Kutny MA, Moser BK, Laumann K, Feusner JH, Gamis A, Gregory J, Larson RA, Powell BL, Stock W, Willman CL et al..  2012.  FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: A report from the Children's Oncology Group.. Pediatric blood & cancer. Abstract
H
Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA et al..  2011.  Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric/adult AML: a report from the Children's Oncology Group and SWOG.. Blood. 118(17):4561-6. Abstract
G
Gu Z, Churchman M, Roberts K, Li Y, Liu Y, Harvey RC, McCastlain K, Reshmi SC, Payne-Turner D, Iacobucci I et al..  2016.  Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.. Nature communications. 7:13331. Abstract
Gallagher RE, Moser BK, Racevskis J, Poiré X, Bloomfield CD, Carroll AJ, Ketterling RP, Roulston D, Schachter-Tokarz E, Zhou D-C et al..  2012.  Treatment-influenced associations of PML-RARα mutations, FLT3 mutations and additional chromosome abnormalities in relapse acute promyelocytic leukemia.. Blood. Abstract
D
Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd L, Willman CL, Bloomfield CD, Paietta E, Gallagher RE et al..  2013.  All-trans retinoic acid and late relapses in acute promyelocytic leukemia: Very long-term follow-up of the North American Intergroup Study I0129.. Leukemia research. Abstract
C
Coutre SE, Othus M, Powell B, Willman CL, Stock W, Paietta E, Levitan D, Wetzler M, Attar EC, Altman JK et al..  2014.  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.. British journal of haematology. Abstract
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C et al..  2015.  Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.. PloS one. 10(4):e0118485. Abstract
B
Becker PS, Kopecky KJ, Wilks AN, Chien S, Harlan JM, Willman CL, Petersdorf SH, Stirewalt DL, Papayannopoulou T, Appelbaum FR.  2009.  Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia.. Blood. 113(4):866-74. Abstract